Review criteria
===============

-   A search of 11 electronic databases and websites was conducted to identify potentially relevant guidelines published in 2006 or later, in addition to use of a review article by Speijers et al.

-   Relevant guidelines were selected based on PIPOH criteria, which were delineated prior to collating the literature.

-   Authors identified the evidence supporting follow-up recommendations in each guideline.

-   Authors appraised guideline quality using AGREE II.

Message for the clinic
======================

-   Melanoma follow-up recommendations concerning frequency of physical examinations, duration of follow-up appointments and use of imaging or diagnostic tests are based mostly on low-level evidence or consensus expert opinion. The level of uncertainty associated with these recommendations is often not apparent from the way the guideline is presented for the development.

-   Clinicians should further investigate the metho-dology and evidence supporting melanoma follow-up recommendations before applying them in the clinical setting.

Background
==========

Australia and New Zealand have the highest incidence of melanoma in the world, with an age-standardised incidence in Australia of 48.8 per 100,000 in 2008, meaning that the average person has a 1 in 18 risk of being diagnosed with the disease before age 85 [@b1],[@b2]. Data from the 2008 American Joint Committee on Cancer Melanoma Staging Database show that 10-year survival rates range from 93% for stage IA to 39% for stage IIC [@b3]. In Australia, melanoma patients had the third highest 5-year survival rates of all cancers at 92% from 1998 to 2004 [@b4]. Consequently, in Australia and other developed nations, there is a growing pool of melanoma survivors who will require follow up for disease recurrence. Evidence-based guidance is needed on how often and what type of follow up is required for these patients. Patient follow up is characterised by appointments where physical examinations and/or diagnostic tests are performed in accordance with a prescribed schedule. Follow up serves a number of purposes: to facilitate the early detection of recurrent tumours and to enable swift action to be taken if a recurrence is detected [@b5], to reassure patients, to provide a vehicle for continuing education regarding skin self-assessment, for management of treatment-related side effects and an opportunity to provide psychosocial support [@b6].

Guidelines may be described as 'systematically developed statements to assist practitioner and patient decisions about appropriate healthcare for specific clinical circumstances' [@b7]. Guideline recommendations may be based on either scientific evidence or the expertise of the guideline developers via a consensus decision-making process. Central to the development of evidence-based guidelines, as opposed to consensus-based guidelines, is a critique of the quality and strength of evidence supporting recommended courses of action and the selection of the best available evidence through a rigorous systematic review of the available literature [@b8].

Guideline recommendations vary between countries or agencies of origin, and this is often thought to be because of the need to 'localise' the available international evidence so that it is relevant to clinical practice within the targeted health system and target population. However, a recent comparison of seven guidelines for the management of posttraumatic stress disorder has noted that differences between guidelines are often because of insufficient empirical data to drive the recommendations [@b9]. When research evidence is limited, transparency and rigour in guideline development are imperative to assist the interpretation of guideline recommendations. The Guidelines International Network (GIN), formed in Paris in 2002 [@b10], seeks to improve the quality of guideline development and reduce inappropriate variation through the establishment and promotion of high-quality standards of guideline development [@b10]. In 2003, the AGREE (Appraisal of Guidelines for Research and Evaluation) collaboration published well-defined methodological criteria for guideline development [@b11] which were updated (AGREE II) in 2010 [@b8]. Nevertheless, two reviews of clinical practice guidelines, published in 2007 and 2009, dealing with prevention of cardiovascular disease and prostate cancer follow up, respectively, found that guidelines were mostly of poor methodological quality and lacked transparency [@b12],[@b13]. Given the increasing need for guidance on the clinical follow up of melanoma survivors, it would be helpful to know whether the available 'evidence-based' guidelines can be trusted. This study aims to determine whether clinical practice guidelines on the follow up of patients diagnosed with cutaneous melanoma are evidence based; evaluate whether the processes used to develop these guidelines were rigorous and transparent; and ascertain whether practice recommendations are consistent across the guidelines.

Methods
=======

Selection of cutaneous melanoma follow-up guidelines
----------------------------------------------------

A search of 11 electronic databases and websites was conducted in February 2013 to identify potentially relevant guidelines: EMBASE; PubMed (Medline); Australian Government National Health and Medical Research Council (NHMRC) Guidelines Portal; National Guidelines Clearinghouse (NGC); GIN Library; Ontario Guideline Advisory Committee (GAC); Canadian Agency for Drugs and Technology in Health (CADTH); National Health Services (NHS) Guidelines Finder; Royal College of Physicians (RCP) Guideline Database; National Institute of Health and Clinical Excellence (NICE); New Zealand Guidelines Group (NZGG) and Scottish Intercollegiate Guidelines Network (SIGN). In addition, a recent review article by Speijers et al. [@b14] citing 19 mostly European melanoma follow-up guidelines (15 of which were published in 2006 or later) was used to source guidelines that might not have been indexed in the standard databases.

The database search was not specific for follow up, instead aiming to retrieve all guidelines specific to skin cancer, to capture more general guidelines which include a description of melanoma follow up. Terms used in the search were *melanoma*, *skin*, *cutaneous*, *dermal*, *cancer*, *neoplasm* and *tumour*. Guidelines published, revised or reaffirmed during the period from 2006 to February 2013 were included. Only one clinical practice guideline per independent organisation, i.e. the most recently published full guideline, was selected.

The study selection process (Figure[1](#fig01){ref-type="fig"}) applied PIPOH [@b15] selection criteria. To reduce bias, these criteria were delineated prior to collating the literature and included: patient population (people with suspected or proven diagnosis of cutaneous melanoma), intervention (follow up of melanoma patients), professionals or target audience of the guideline (general practitioners, oncologists, dermatologists, surgeons, physicians or other referred specialists) and healthcare setting (primary, secondary or tertiary). In addition, guidelines were excluded if they: had only recommendations that were developed solely on the basis of consensus; were summaries of another guideline; were not in English (or translated into English); had no explicit grading system for determining the strength of recommendations; had no melanoma follow-up recommendations; referred to another guideline for all melanoma follow-up recommendations; were not based on a systematic literature review; were replaced by a more recent version of the guideline or had expired (past the stated due date for updating).

![Diagram of guideline selection](ijcp0068-0761-f1){#fig01}

Initial guideline eligibility on the basis of the collated guidelines was conservatively determined by two authors. When consensus could not be reached, another two reviewers independently assessed the guideline in question and the majority decision prevailed. Melanoma follow-up recommendations were extracted from each guideline and compared, and the evidence cited as supporting each recommendation was also extracted.

Evaluation of guidelines
------------------------

The AGREE II instrument provided a framework to assess the comparative quality of the different guidelines [@b8]. This tool was used by the four authors to independently assess each guideline. The authors provided a range of experience in guideline development and evaluation, with perspectives including an experienced guideline developer and methodologist, a clinician, a public health academic and a research assistant.

The AGREE II instrument is comprised of 23 items under six domains: scope and purpose, stakeholder involvement, rigour of development, clarity of presentation, applicability and editorial independence (see Table[1](#tbl1){ref-type="table"} for descriptions of each item). Each item is given a rating by assessors from 1 to 7, with 1 indicating 'strongly disagree' and 7 indicating 'strongly agree' [@b8].

###### 

AGREE II instrument domains and items

  Domain                    Item   
  ------------------------- ------ -----------------------------------------------------------------------------------------------------------
  Scope and purpose         1      The overall objective(s) of the guideline is (are) specifically described
                            2      The health question(s) covered by the guideline is (are) specifically described
                            3      The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described
  Stakeholder involvement   4      The guideline development group includes individuals from all relevant professional groups
                            5      The views and preferences of the target population (patients, public, etc.) have been sought
                            6      The target users of the guideline are clearly defined
  Rigour of development     7      Systematic methods were used to search for evidence
                            8      The criteria for selecting the evidence are clearly described
                            9      The strengths and limitations of the body of evidence are clearly described
                            10     The methods for formulating the recommendations are clearly described
                            11     The health benefits, side effects and risks have been considered in formulating the recommendations
                            12     There is an explicit link between the recommendations and the supporting evidence
                            13     The guideline has been externally reviewed by experts prior to its publication
                            14     A procedure for updating the guideline is provided
  Clarity of presentation   15     The recommendations are specific and unambiguous
                            16     The different options for management of the condition or health issue are clearly presented
                            17     Key recommendations are easily identifiable
  Applicability             18     The guideline describes facilitators and barriers to its application
                            19     The guideline provides advice and/or tools on how the recommendations can be put into practice
                            20     The potential resource implications of applying the recommendations have been considered
                            21     The guideline presents monitoring and/or auditing criteria
  Editorial independence    22     The views of the funding body have not influenced the content of the guideline
                            23     Competing interests of guideline development group members have been recorded and addressed

In accordance with AGREE II methodology, mean domain scores were calculated by summing up all the scores of the individual items in a domain and by scaling the total as a percentage of the maximum possible score for that domain across all the four reviewers (see Figure[2](#fig02){ref-type="fig"}) [@b8]. The six domain scores are independent and are not intended to be aggregated into a single overall quality score; rather, appraisers give a separate overall score of 1--7 and are asked whether they would recommend the guideline for use [@b8]. An average overall score for each guideline was calculated using the overall scores of the four reviewers.

![Example calculation of an AGREE II domain score](ijcp0068-0761-f2){#fig02}

Results
=======

The guideline selection process is represented diagrammatically in Figure[1](#fig01){ref-type="fig"}. A total of 3981 records were retrieved in the initial literature search, although the vast majority of these were excluded after screening of title and abstract because they were unrelated to melanoma, skin cancer or cancer screening/surveillance or not clinical practice guidelines. Subsequently, the remaining 53 guidelines were evaluated, and following the application of PIPOH criteria and use of the consensus process, 44 guidelines were excluded. Reasons for exclusion included guidelines not in English (*n *= 12); guidelines with no recommendations (*n *= 11); guidelines were not the most recent publication (*n *= 9); non-original guidelines (*n *= 6); not based on systematic review (*n *= 3); patient-oriented guidelines (*n *= 2) and no recommendation grading system (*n *= 1).

The included guidelines (*n *= 9) are listed in Table[2](#tbl2){ref-type="table"}. Included guidelines were published by organisations from the United States (*n *= 4); Australia and New Zealand (*n *= 1); Scotland (*n *= 1); the United Kingdom (*n *= 1); Switzerland (*n *= 1) and Europe (*n *= 1).

###### 

Guidelines included in analysis of follow-up recommendations

  Guideline title                                                                                  Organisation                                                                                 Scope                                           Year, Countries
  ------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------- ----------------------------------------------- ------------------------------------------------------
  Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand         Cancer Council Australia; Australian Cancer Network; Ministry of Health, New Zealand (CCA)   Cutaneous melanoma                              2008, Australia and New Zealand
  Cutaneous melanoma. A National Clinical Guideline                                                Scottish Intercollegiate Guidelines Network (SIGN)                                           Cutaneous melanoma                              2003 (updated 2004, reaffirmed 2007, 2011), Scotland
  Revised UK Guidelines for the Management of Cutaneous Melanoma 2010                              British Association of Dermatologists (BAD)                                                  Cutaneous melanoma                              2010, UK
  Evidence-based Clinical Practice Guideline: Treatment of Cutaneous Melanoma                      American Society of Plastic Surgeons (ASPS)                                                  Cutaneous melanoma                              2007, USA
  Long-term Follow-up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers   Children\'s Oncology Group (COG)                                                             General health and common adult onset cancers   2006 (updated 2008), USA
  Guidelines of Care for the Management of Primary Cutaneous Melanoma                              American Academy of Dermatology (AAD)                                                        Cutaneous melanoma                              2011, USA
  Cutaneous Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up     European Society for Medical Oncology (ESMO)                                                 Cutaneous melanoma                              2012, Europe
  Updated Swiss Guidelines for the Treatment and Follow up of Cutaneous Melanoma                   Project Group Melanoma of the Swiss Group for Clinical Cancer Research (SAKK)                Cutaneous melanoma                              2011, Switzerland
  Melanoma                                                                                         National Comprehensive Cancer Network (NCCN)                                                 Cutaneous melanoma                              2012, USA

Melanoma follow-up recommendations
----------------------------------

Recommendations for the follow up of cutaneous melanoma from each guideline were compiled for comparing the evidence base used by each guideline and to determine the consistency of the guidance that was formulated. All guidelines dealt with the self-examination and education aspect of follow up and all guidelines made at least one recommendation regarding frequency and duration of follow up. All guidelines except COG [@b16] made recommendations concerning the imaging/diagnostic test components of melanoma follow up.

### Self-examination and education

All guidelines agreed that patients should be taught skin self-examination as this was the method by which recurrences were most commonly detected [@b16]--[@b24]. In addition, educating family members about self-examination was recommended by ASPS [@b18]. Education about sun-smart behaviour at routine visits was recommended by CCA [@b19], ESMO [@b22], SAKK [@b23] and NCCN [@b21]. The recommendation, found in all the guidelines, that patients should be educated in self-examination to support early detection, is based primarily on consensus and/or clinical experience. To support this recommendation, each of the guidelines used evidence which was different from that used in any other guideline. In addition, the evidence content varied between guidelines: CCA guidelines relied on evidence showing that most patients detect their own recurrence [@b19]; ASPS guidelines relied on the finding that second primaries are thinner than first primaries or are thinner in those patients who are educated [@b18]; American Academy of Dermatology (AAD) relied on both [@b20]. SIGN guidelines relied on evidence showing that information provision can reduce distress and possibly thereby improve survival [@b17]. COG, ESMO, SAKK, NCCN and BAD provided no evidence to support this recommendation [@b16],[@b21]--[@b24].

### Follow-up frequency and duration

Recommendations for the frequency and duration of follow up are summarised in Table[3](#tbl3){ref-type="table"}. CCA was the only guideline to mention that the frequency of follow up may be affected if a patient is enrolled in a clinical trial [@b19]. Although all guidelines recommended follow up for medium-to--high-risk melanoma patients, they offered little or no evidence to support its use. CCA, AAD, ASPS, BAD and SAKK acknowledged that most melanoma recurrences are detected by the patient [@b18]--[@b20],[@b23],[@b24], but BAD also suggested that physician detection of melanoma is important [@b24]. A prospective study by Garbe et al. [@b25] that claims to demonstrate the efficacy of routine follow up was cited by CCA, SIGN and the AAD guidelines [@b17],[@b19],[@b20], although the study does not exclude the possibility of lead time bias. The BAD [@b24] guidelines referenced a consensus-based guideline also written by Garbe et al. [@b26]. The SAKK [@b23] guidelines share some authors with the ESMO [@b22] guidelines and cite another German guideline written by Garbe et al. [@b27]. The SAKK and ESMO guidelines also cite each other [@b22],[@b23]. The CCA, ASPS, SIGN and AAD [@b17]--[@b20] guidelines cite a range of studies that show there is no survival advantage for patients receiving intense routine surveillance: Baughan et al. [@b28] cited by CCA; Hofmann et al. [@b29] cited by CCA, ASPS and AAD; Shumate et al. [@b30] cited by SIGN; Mooney et al. [@b31] cited by SIGN and CCA; Tsao et al. [@b32] cited by ASPS. The NCCN guidelines only cite studies published in the early 1990s relating to psychosocial support, detection of a subsequent secondary primary melanoma and screening for second non-melanoma primary malignancies as reasons in favour of a structured follow-up programme [@b21]. ESMO\'s only recommendation relating to frequency of follow up states that there is no consensus on the optimal schedule [@b22].

###### 

Follow-up frequency and duration

  Guideline   Recommendations
  ----------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  CCA         Stage 0: No recommendation Stage I: 2/year (first 5 years), then 1/year Stage II: 3--4/year (first 5 years), then 1/year Stage III: 3--4/year (first 5 years), then 1/year Stage IV: No recommendation
  SIGN        Stage 0: No follow up required Stages I--III: 'longer in stage III than in stages I and II' Stages III--IV: 'lifelong follow up may be necessary for stages III and IV'
  BAD         Stage 0: No follow up required Stage IA: 2--4/year (first year), then discharge Stages IB--IIIA: 4/year (first 3 years), then 2/year (next 5 years), then discharge Stages IIIB-C and resected IV: further follow up of 1/year (for 10 years)
  ASPS        No stage specified: 4/year (first year), then 2/year (for 5 years), then at least 1/year (more frequently for high-risk patients)
  COG         No stage specified: Annual follow up with monthly self-exam
  AAD         No stage specified: Annual follow up
  ESMO        There is no consensus on the optimal follow-up schedule and frequency of follow up
  SAKK        Stage 0: No recommendation Stage I (≤T1N0): every 6 months (years 1--3), every 12 months (years 4--10) Stages I (T2N0), IIA, IIB: every 6 months (years 1--3), every 12 months (years 4--5), every 6--12 months (years 6--10) Stages IIC, III: every 3 months (years 1--5), every 6 months (years 6--10) Stage IV: 'individual'
  NCCN        Stage 0: At least annual skin exam for life; monthly self skin exam Stages IA--IIA: every 3--12 months (first 5 years), then annually as clinically indicated, monthly self skin exam Stages IIB--IV: every 3--12 months (first 5 years), then every 3--12 months (for 3 years), then annually as clinically indicated; monthly skin self-examination

Text in quotations is taken directly from the guidelines.

### Diagnostic/imaging tests

Recommendations for the use of diagnostic/imaging tests as part of follow-up care are summarised in Table[4](#tbl4){ref-type="table"}. All the recommendations for the use of tests in follow up are based on low-level evidence, primarily case series, diagnostic accuracy studies or prognostic cohort studies. With one exception, the studies used to support the SIGN [@b17] guideline recommendations were published before 2000. Similarly, the studies used by CCA [@b19] to reject the use of tests except for ultrasound are also pre-2000. NCCN [@b21] cites studies that report low yield, significant rates of false positives and risks of radiation exposure from medical imaging, but still recommend that imaging should be considered in some cases. CCA and SAKK recommend the use of ultrasound in high-risk patients [@b19],[@b23], whereas AAD and SIGN -- using similar evidence -- do not [@b17],[@b20]. ESMO recommends a serum S-100 blood test instead of lactate dehydrogenase because it has higher specificity for disease progression, i.e. 'if any blood test is done at all' [@b22], and in another recommendation states that there is no consensus on the utility of imaging and blood tests [@b22].

###### 

Diagnostic/imaging tests

  Guideline     Ultrasound            Chest X-rays                                                      CT scans                      PET-CT scans                 MRI                          Liver function tests   Blood test/count    Lactate dehydrogenase   Serum S-100
  ------------- --------------------- ----------------------------------------------------------------- ----------------------------- ---------------------------- ---------------------------- ---------------------- ------------------- ----------------------- ---------------------
  CCA           Stage IV              No                                                                No                            No                                                                               No                  No                      
  SIGN          No                    No                                                                No                                                                                      No                     No                  No                      
  BAD                                 No                                                                Consider in stages IIIB--IV   No                           No                                                  No                  Stage IV                
  ASPS [@b18]                         Stage II or II, and patients with possible systemic involvement                                                                                                                  Stages II and III   Stages II and III       
  COG                                                                                                                                                                                                                                                              
  AAD           No                    No                                                                No                            No                                                                               No                  Stage IV                
  ESMO                                                                                                                                                                                                                                     No                      Yes
  SAKK          Stages I (T2N0)--IV   Stages I (T2N0)--IV                                               Stages IIC--IV                Stages IIC--IV               Stages IIC--IV                                                                                  Stages I (T2N0)--IV
  NCCN                                Consider in stages IIB--IV                                        Consider in stages IIB--IV    Consider in stages IIB--IV   Consider in stages IIB--IV                                                                      

'No' indicates that the test was recommended against. Blank areas indicate that no recommendation was made.

AGREE II domains
----------------

The AGREE II instrument domain scores for each guideline, averaged across the four reviewers, are given in Table[5](#tbl5){ref-type="table"}. The two domains of greatest interest for the authors, given the purpose of this study, were 'rigour of development' and 'overall guideline quality'.

###### 

AGREE II instrument domain scores

  Guideline   Scope and purpose (%)   Stakeholder involvement (%)   Rigour of development (%)   Clarity of presentation (%)   Applicability (%)   Editorial independence (%)   Average overall score   Would you recommend this guideline for use?
  ----------- ----------------------- ----------------------------- --------------------------- ----------------------------- ------------------- ---------------------------- ----------------------- ---------------------------------------------
  CCA         61                      83                            95                          85                            26                  44                           5.8                     3 Yes 1 Yes, with modifications
  SIGN        61                      86                            60                          86                            61                  10                           5.0                     4 Yes, with modifications
  BAD         33                      54                            50                          94                            42                  46                           5.0                     2 Yes 2 Yes, with modifications
  ASPS        47                      26                            44                          75                            3.1                 2.1                          4.0                     3 Yes, with modifications 1 No
  COG         71                      93                            79                          82                            42                  79                           6.0                     4 Yes
  AAD         60                      31                            29                          74                            3.1                 83                           2.8                     4 No
  ESMO        15                      21                            20                          65                            4.2                 27                           2.5                     4 No
  SAKK        46                      25                            21                          39                            8.3                 56                           3.0                     4 No
  NCCN        28                      44                            29                          60                            14                  35                           3.5                     4 Yes, with modifications
  Mean        46.9                    51.4                          47.4                        73.3                          22.6                42.5                                                 

### Rigour of development

This domain encompasses 8 of the 23 items in the AGREE II instrument [@b8]. Methods used to search for evidence were adequate in most guidelines, but only CCA [@b19] searched a wide variety of databases, listed time periods searched, search terms used and included an appendix detailing the whole search strategy. Description of the criteria used for selecting evidence was relatively poor for most guidelines, with some guidelines only mentioning language type and most not mentioning eligibility criteria such as study design or health outcomes of interest. A formal grading system and appraisal of literature were necessary for the guideline to receive a high AGREE score on this domain because the system enables a description of the strengths and limitations of the guidelines' body of evidence. In addition, it was essential that there was some consideration of consistency of results across studies and their applicability in practice. Expert consensus was often stated as the method used for formulating recommendations. Guidelines that described their methods for obtaining consensus \[COG [@b16]\] scored more highly than those merely stating that a consensus process had been employed \[ASPS [@b18]\]. ESMO, SAKK and NCCN guidelines did not state any method for formulating recommendations [@b21]--[@b23]. Health benefits, side effects and risks were adequately outlined in most guidelines, nevertheless appraisers thought that the explicit discussion of complications and side effects was lacking in AAD and ASPS [@b18],[@b20]. The way that guidelines linked evidence to recommendations varied greatly. The most transparent format was that of the NHMRC-endorsed CCA [@b19] guidelines, which comprised an evidence summary box with references and grading of the level of evidence for each individual recommendation. Most guidelines were able to demonstrate congruency between the evidence and the recommendations. The ESMO guidelines provided in-text referencing, but lacked a link between recommendations and evidence [@b22]. Guidelines with no expert external review at all were scored poorly, whereas those with detailed explanations of the purpose, method and outcomes received higher scores. Guidelines that included information about how outcomes of the external review were applied to the guideline development process generally scored higher than those that did not. Better guidelines usually included a methodology or timeline for updating the guideline rather than a simple statement that the guideline would be updated.

### Overall guideline quality

Ultimately, the COG [@b16] guidelines were rated as having the best quality, with highest scores in two of six domains. The CCA [@b19] guidelines were also unanimously recommended for use; however, one reviewer noted that there were some gaps in the guideline, such as the lack of auditing criteria. Modifications suggested for the SIGN [@b17] guidelines included better discussion of article selection, applicability and more information regarding editorial independence. Two appraisers would modify the BAD [@b24] guidelines to include detailed criteria for selecting evidence and consideration of potential resource implications of applying the recommendations. The ASPS [@b18] guideline was recommended with modifications by three appraisers and not recommended by one on the grounds that the guideline was generally vague and tended to describe current practice rather than provide evidence-based recommendations. The other three reviewers noted that although there were deficiencies in some applicability and editorial independence items, methodological rigour and clarity of presentation were good. The AAD [@b20] guidelines received higher domain scores than ASPS [@b18] in three of the six domains, and equal scores in another domain and slightly less than ASPS in another domain. Nevertheless, ASPS [@b18] received more favourable recommendations than AAD [@b20], with the appraisers noting that AAD guidelines -- according to AGREE criteria -- lacked transparency, rigour and multidisciplinary engagement. NCCN [@b21] guidelines did not report on some of the methodological features included in other guidelines, but were clearly presented and slightly more rigorous than SAKK guidelines [@b23]. ESMO [@b22] guidelines were brief and did not report on most methodological features usually expected to be included in an evidence-based clinical practice guideline.

Discussion
==========

Summary of main finding
-----------------------

The paucity of evidence in the field of melanoma follow up has been borne out by the comparison of melanoma follow-up guidance in this review. All guidelines described the lack of evidence to support guidance on the frequency of follow-up visits. As there is no international consensus regarding what constitutes best practice for follow up of melanoma survivors, the recommendations included in the guidelines are based primarily on the relapse profile over time. Generally, the guidelines propose that the more advanced the stage of disease, the more frequent the appointments should be and that the frequency should be higher during the early follow-up period as recurrence is more likely in patients with advanced disease [@b33] and in the first years following diagnosis [@b34]. However, the intervals prescribed are 'arbitrary' and there is significant variation in the recommendations that have been made [@b19]. Similarly, as the evidence base for the effectiveness of skin examination and diagnostic imaging was also sparse and of low quality, the ensuing recommendations made by guideline developers have been largely developed through consensus and vary as a consequence.

Context of this review with other literature
--------------------------------------------

These findings are very similar to those of a systematic review of clinical practice guidelines dealing with prostate cancer follow up [@b12], which also revealed poor methodological quality and lack of transparency in consensus procedures, in the context of paucity of evidence in that field of research. Another study assessing six British cardiovascular guidelines published by professional societies using AGREE II found serious methodological deficiencies in all guidelines and did not recommend any guideline for clinical practice [@b13]. In recent years, approaches have been developed to increase transparency in the development of guideline recommendations, most noticeably the Australian FORM system, recommended by the National Health and Medical Research Council (NHMRC) [@b35], which mandates the use of an evidence statement form that transparently depicts how developers move from evidence to making a judgement and formulating a recommendation. This methodological approach was used by the CCA guideline, which received the highest scores in our AGREE II evaluation with regards to rigour of development. Similarly, the GRADE system -- which has been promoted heavily worldwide -- provides a more standardised approach to the development of recommendations [@b36]. None of the guidelines appeared to use GRADE when formulating recommendations.

Strengths and limitations
-------------------------

Some guidelines may have scored poorly as a result of insufficient reporting, rather than deficient quality. A potential weakness of this study is that guideline authors were not contacted to confirm findings. Hence, the scores might not be an accurate reflection of the guideline development process. Alternatively, they may highlight problems in reporting by guideline development groups.

The AGREE II instrument has some potential weaknesses, e.g. the items and scoring system may be interpreted differently by appraisers, regardless of the application of the 'user\'s manual description', 'how to rate' and 'additional considerations' sections provided for each item [@b8]. Moreover, it was suggested by one appraiser that the addition of an item to specifically assess the provision of tools for patients that complement clinical practice guidelines would be beneficial.

It should also be noted that AGREE II scores do not aim to rate the quality of the recommendations or their supporting evidence [@b8]. For example, COG [@b16] guidelines attained a relatively high 'rigour of development' score, yet the evidence provided in that guideline for melanoma follow up was limited. Therefore, caution should be exercised as guideline quality according to AGREE II domains reflects the methodology of the guideline development and does not reflect the availability of good evidence [@b8]. Nevertheless, it is evident that guidelines with low scores in the rigour of development domain tended to provide less evidence for their recommendations.

Following the completion of our literature searches and data analysis, NCCN released their annual update to their guideline. Their melanoma follow-up guidance remains unchanged. This change does not impact on the findings of this study. The SIGN guidelines were reaffirmed in 2011 and remain current, although SIGN recommends the guidelines be used with caution as they are over 7 years old.

Conclusions and implications
----------------------------

This review examines current international guideline recommendations for follow up of patients with cutaneous melanoma. The evidence base for each guideline was evaluated and the AGREE II instrument was utilised for the appraisal of guideline quality. Although most recommendations were evidence based, the level and strength of evidence employed was often low. Moreover, given the lack of clear direction from the evidence base, recommendations were often inconsistent between guidelines. All guidelines acknowledged the lack of evidence to some extent and the need for further research in the field of melanoma follow up. Clinicians should recognise that further investigation into the methodology and evidence behind the development of recommendations are required to fully understand the significance of melanoma follow-up recommendations in the clinical setting.
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